April 24 (Reuters) - Bluebird bio BLUE.O said on Monday it has submitted a marketing application to the U.S. Food and Drug Administration for its gene therapy to treat sickle cell disease, a blood disorder.
The company said its application to the health regulator included a request for priority review.
(Reporting by Bhanvi Satija in Bengaluru; Editing by Devika Syamnath)
((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.